Sai Life Sciences quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	554	496	+11.7%
EBITDA	148	121	+22.4%
EBITDA margin	26.7%	24.4%	+2.3 pts
Profit before tax	98.0	80.7	+21.3%
Net profit	73.3	60.5	+21.2%
EPS	₹3.46	₹2.90	+19.3%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024

Expenses
	554	602	556	537	496	580	440
	3.5	15.5	8.4	15.3	9.9	9.6	9.1
	558	618	565	553	506	589	449
	178	159	114	204	160	157	122
	−32.9	2.5	13.7	−63.4	−18.4	10.9	−0.7
	180	187	173	163	161	151	133
	7.6	7.8	9.7	9.4	12.4	10.9	23.1
	45.9	45.3	44.1	39.7	37.7	37.5	34.1
	81.5	77.2	67.7	88.7	73.8	103	66.3
	460	479	422	441	426	470	377
	148	177	188	146	121	158	120
	102	131	144	106	83.2	120	85.7
Profit
	98.0	139	142	112	80.7	119	71.6
	0.0	0.3	−8.3	0.0	0.0	0.0	0.0
	98.0	139	134	112	80.7	119	71.6
	19.7	13.3	31.4	29.7	14.1	17.5	9.9
	5.0	21.7	2.4	−1.4	6.2	13.0	7.9
	24.7	35.0	33.8	28.2	20.3	30.5	17.8
	73.3	104	100	83.8	60.5	88.3	53.9
	73.3	104	100	83.8	60.5	88.3	53.9
	19.7	−9.1	0.9	−14.2	1.6	7.3	−3.9
	93.0	95.1	101	69.6	62.1	95.6	50.0
	—	—	100	83.8	—	—	—
Per share
	₹3.46	₹4.93	₹4.77	₹4.01	₹2.90	₹4.24	₹2.89
	₹3.42	₹4.87	₹4.71	₹3.93	₹2.83	₹4.14	₹2.84
Other comprehensive income — detail
	19.7	−9.1	0.9	−14.2	1.6	7.3	—
	0.1	1.6	0.9	−0.9	−0.1	1.3	−0.3
	0.0	0.4	0.2	−0.2	−0.0	0.3	—
	—	—	—	—	—	—	−0.1
	26.2	−15.1	0.1	−18.9	2.2	8.5	−5.3
	6.6	−4.8	−0.2	−5.4	0.5	2.1	—
	—	—	—	—	—	—	−1.7
	—	—	100	—	—	—	—
Per share — as-filed variants
	₹3.46	₹4.93	₹4.77	₹4.01	₹2.90	₹4.24	₹2.89
	₹3.42	₹4.87	₹4.71	₹3.93	₹2.83	₹4.14	₹2.84
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	409	440	429	397	355	412	319
	73.9%	73.1%	77.0%	73.9%	71.6%	71.1%	72.5%
Adjusted (ex-exceptional items) — derived
	98.0	139	142	112	80.7	119	71.6
	0.0	0.3	−8.3	0.0	0.0	0.0	0.0
	73.3	104	107	83.8	60.5	88.3	53.9
	₹3.46	₹4.92	₹5.06	₹4.01	₹2.90	₹4.24	₹2.89

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SAILIFE₹1,487.20

Sai Life Sciences Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSYNGENE DIVISLAB PPLPHARMA NH NEULANDLAB NATCOPHARM LALPATHLAB COHANCEMcap ₹31,496 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	439.8	579.5	496.4	537.5	556.5	602.1	554.3
Other Income	9.1	9.6	9.9	15.3	8.4	15.5	3.5
Total Income	448.9	589.1	506.3	552.8	564.8	617.7	557.8
Expenses
+ Cost of Materials Consumed	121.5	156.9	159.5	203.5	114.2	159.2	177.9
+ Changes in Inventories	-0.7	10.9	-18.4	-63.4	13.7	2.5	-32.9
+ Employee Benefit Expense	132.9	151.1	160.6	162.8	173.0	186.7	179.9
+ Finance Costs	23.1	10.9	12.4	9.4	9.7	7.8	7.6
+ Depreciation & Amortisation	34.1	37.5	37.7	39.7	44.1	45.3	45.9
+ Other Expenses	66.3	103.1	73.8	88.7	67.7	77.2	81.5
Total Expenses	377.2	470.3	425.6	440.7	422.4	478.7	459.9
EBITDA	119.8	157.6	120.9	145.8	187.9	176.5	148.0
EBIT	85.7	120.1	83.2	106.1	143.8	131.2	102.1
Profit
PBT before Exceptional Items	71.6	118.8	80.7	112.1	142.5	138.9	98.0
+ Exceptional Items	0.0	0.0	0.0	0.0	-8.3	0.3	0.0
Pretax Income	71.6	118.8	80.7	112.1	134.2	139.2	98.0
+ Current Tax	9.9	17.5	14.1	29.7	31.4	13.3	19.7
+ Deferred Tax	7.9	13.0	6.2	-1.4	2.4	21.7	5.0
Tax Expense	17.8	30.5	20.3	28.2	33.8	35.0	24.7
Net Income	53.9	88.3	60.5	83.8	100.4	104.2	73.3
+ Net Income — Continuing Ops	53.9	88.3	60.5	83.8	100.4	104.2	73.3
+ Other Comprehensive Income	-3.9	7.3	1.6	-14.2	0.9	-9.1	19.7
Total Comprehensive Income	50.0	95.6	62.1	69.6	101.3	95.1	93.0
Net Income to Common	—	—	—	83.8	100.4	—	—
Per Share
Basic EPS	2.89	4.24	2.90	4.01	4.77	4.93	3.46
Diluted EPS	2.84	4.14	2.83	3.93	4.71	4.87	3.42
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	7.3	1.6	-14.2	0.9	-9.1	19.7
+ Items NOT to be Reclassified to P&L	-0.3	1.3	-0.1	-0.9	0.9	1.6	0.1
+ Tax on Items NOT to be Reclassified	—	0.3	-0.0	-0.2	0.2	0.4	0.0
+ Tax on Items NOT to be Reclassified — alt tag	-0.1	—	—	—	—	—	—
+ Items to be Reclassified to P&L	-5.3	8.5	2.2	-18.9	0.1	-15.1	26.2
+ Tax on Items to be Reclassified	—	2.1	0.5	-5.4	-0.2	-4.8	6.6
+ Tax on Items to be Reclassified — alt tag	-1.7	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	—	—	—	—	100.4	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	2.89	4.24	2.90	4.01	4.77	4.93	3.46
Diluted EPS — Continuing Operations	2.84	4.14	2.83	3.93	4.71	4.87	3.42
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	318.9	411.8	355.3	397.3	428.5	440.4	409.4
Gross Margin %	72.52	71.06	71.57	73.93	77.01	73.14	73.86
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	71.6	118.8	80.7	112.1	142.5	138.9	98.0
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	-8.3	0.3	0.0
Net Income Adj (tax-effected)	53.9	88.3	60.5	83.8	106.6	104.0	73.3
EPS Adj	2.89	4.24	2.90	4.01	5.06	4.92	3.46
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	20.8	20.8	20.9	21.0	21.1	21.2	21.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Sai Life Sciences Q2 FY27 results date

Sai Life Sciences (NSE: SAILIFE) will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, according to the board-meeting notice it filed on 1 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹73.3 crore, up 21.2% from ₹60.5 crore in Q1 FY26 and down 29.7% from ₹104 crore in Q4 FY26. Revenue from operations was ₹554 crore, up 11.7% year on year and down 7.9% from the previous quarter.

Board-meeting notice filed: 1 October 2026
Q2 FY26 results (a year earlier): 6 November 2025
Q1 FY27 results (the latest): 6 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 5 November 2026Thursday · notice filed 1 Oct
Q1 FY27 net profit: ₹73.3 Cr+21.2% vs Q1 FY26−29.7% vs Q4 FY26
Q1 FY27 revenue: ₹554 Cr+11.7% vs Q1 FY26−7.9% vs Q4 FY26
Q1 FY27 operating margin: 18.4%+1.7 pts vs Q1 FY26−3.4 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹83.8 CrRevenue ₹537 Cr
Q1 FY27 EPS (basic): ₹3.46

Questions

When will Sai Life Sciences announce its Q2 FY27 results?

On 5 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 1 October 2026). Last year it reported Q2 FY26 on 6 November 2025.

What will Sai Life Sciences' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹83.8 crore and revenue from operations ₹537 crore. The latest quarter, Q1 FY27, had a net profit of ₹73.3 crore and revenue of ₹554 crore.

What were Sai Life Sciences' Q1 FY27 results?

Consolidated net profit was ₹73.3 crore, up 21.2% from ₹60.5 crore in Q1 FY26 and down 29.7% from ₹104 crore in Q4 FY26. Revenue from operations was ₹554 crore, up 11.7% year on year and down 7.9% from the previous quarter.

How has Sai Life Sciences' profit changed over the last four quarters?

Net profit by quarter: ₹83.8 crore in Q2 FY26, ₹100 crore in Q3 FY26, ₹104 crore in Q4 FY26 and ₹73.3 crore in Q1 FY27. That is ₹362 crore over the four quarters. Revenue from operations: ₹537 crore, ₹556 crore, ₹602 crore and ₹554 crore.

What was Sai Life Sciences' net profit in FY26?

Consolidated net profit was ₹349 crore in FY26 (April 2025–March 2026), up 105.1% from ₹170 crore in FY25.

What was Sai Life Sciences' revenue in FY26?

Revenue from operations was ₹2,192 crore in FY26 (April 2025–March 2026), up 29.4% from ₹1,695 crore in FY25.

Where do these Sai Life Sciences figures come from?

From Sai Life Sciences' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.